Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Current Deferred Revenue: 2019-2023

Historic Current Deferred Revenue for Cidara Therapeutics (CDTX) over the last 5 years, with Dec 2023 value amounting to $430,000.

  • Cidara Therapeutics' Current Deferred Revenue rose 66.00% to $26.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $26.2 million, marking a year-over-year increase of 66.00%. This contributed to the annual value of $430,000 for FY2023, which is 97.06% down from last year.
  • As of FY2023, Cidara Therapeutics' Current Deferred Revenue stood at $430,000, which was down 97.06% from $14.6 million recorded in FY2022.
  • Cidara Therapeutics' Current Deferred Revenue's 5-year high stood at $14.6 million during FY2022, with a 5-year trough of $430,000 in FY2023.
  • Over the past 3 years, Cidara Therapeutics' median Current Deferred Revenue value was $13.9 million (recorded in 2021), while the average stood at $9.7 million.
  • As far as peak fluctuations go, Cidara Therapeutics' Current Deferred Revenue spiked by 41.44% in 2020, and later slumped by 97.06% in 2023.
  • Cidara Therapeutics' Current Deferred Revenue (Yearly) stood at $9.8 million in 2019, then soared by 41.44% to $13.9 million in 2020, then rose by 0.40% to $13.9 million in 2021, then rose by 4.99% to $14.6 million in 2022, then tumbled by 97.06% to $430,000 in 2023.